Abstract
Six patients with malignant carcinoid disease were given eight courses of therapy with cyclophosphamide. Measurable antitumor effect (decrease in liver size) was variable but decreases in liver size of 40 per cent or greater were noted in four of the eight trials. Symptoms of the carcinoid syndrome exacerbated shortly after the initial administration of the drug. Elevation of urinary 5-HIAA levels and the appearance of other metabolites in the urine occurred consistently with the initial intravenous dose of drug.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
